Volume 10, Number 6—June 2004
Dispatch
Reference Group Choice and Antibiotic Resistance Outcomes
Table 2
Outcome | Cases | Controls | Adjusted analyses |
||
---|---|---|---|---|---|
ORa | Attributable to VRE | p value | |||
Three analyses comparing VRE and uninfected controls |
(n = 99) |
(n = 280) |
|||
Deaths |
12.1% |
6.1% |
2.0b |
– |
0.13 |
Length of stay (d), mean per case |
15.2 |
8.5 |
1.8c |
6.2 |
<0.001 |
Charges ($), mean per case |
46,660 |
27,224 |
1.5d |
13,884 |
<0.001 |
Three analyses comparing VRE and vancomycin-susceptible enterococci (VSE) controls |
(n = 99) |
(n = 213) |
|||
Deaths |
12.1% |
6.6% |
2.5e |
– |
0.04 |
Length of stay (d), mean per case |
15.2 |
13.6 |
1.0f |
– |
0.5 |
Charges ($), mean per case | 46,600 | 31,915 | 1.4g | 12,766 | <0.001 |
aOdds ratio for deaths, and multiplicative effect (ME) for continuous outcomes (length of stay and charges).
bAdjusted for number of comorbid illnesses and admission to the intensive care unit (ICU).
cAdjusted for propensity score [i.e., likelihood of being a VRE case (Appendix)], being transferred from another institution, renal disease, malignancy, and admission to the ICU.
dAdjusted for propensity score (i.e. likelihood of being a VRE case), having had surgery before cohort inclusion, and duration of hospitalization before cohort inclusion.
eAdjusted for surgery, sex, and admission to the ICU.
fAdjusted for duration of hospitalization before cohort inclusion, admission to the ICU, and malignancy.
gAdjusted for having had surgery before inclusion in the cohort, and duration of hospitalization before cohort inclusion.